Literature DB >> 11145192

Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.

N Shiraki1, A Hamada, K Yasuda, J Fujii, K Arimori, M Nakano.   

Abstract

The objective of this study was to determine whether human immunodeficiency virus (HIV) protease inhibitors (saquinavir, ritonavir and nelfinavir) interact with other HIV protease inhibitors and/or HIV reverse transcriptase inhibitors (zidovudine, didanosine, lamivudine, zalcitabine and sanilvudine). We measured transport of nelfinavir, an HIV protease inhibitor which is known as a substrate for the multidrug resistance transporter P-glycoprotein (P-gp), in an epithelial monolayer model and Ki for P-gp of some drugs by a calcein flux assay. Transport in a basal to apical direction was 2-fold greater than apical to basal flux for nelfinavir, Ki for P-gp of a potent P-gp inhibitor cyclosporin A was 1.09 microM and those of ritonavir and nelfinavir were 111 microM and 28.6 microM, whereas all HIV reverse transcriptase inhibitors gave high K1 values. These data show that nelfinavir, which is a substrate for P-gp, inhibits a P-gp function as a drug efflux pump and that HIV reverse transcriptase inhibitors do not inhibit P-gp.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11145192     DOI: 10.1248/bpb.23.1528

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  10 in total

Review 1.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

2.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.

Authors:  Ondrej Martinec; Martin Huliciak; Frantisek Staud; Filip Cecka; Ivan Vokral; Lukas Cerveny
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

5.  The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.

Authors:  Omar Janneh; Andrew Owen; Patrick G Bray; David J Back; Munir Pirmohamed
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

6.  Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.

Authors:  Jennifer Ford; Marta Boffito; Adrian Wildfire; Andrew Hill; David Back; Saye Khoo; Mark Nelson; Graeme Moyle; Brian Gazzard; Anton Pozniak
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

7.  P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.

Authors:  Hiromi Fujimoto; Maiko Higuchi; Hiroshi Watanabe; Yasuhiro Koh; Arun K Ghosh; Hiroaki Mitsuya; Naomi Tanoue; Akinobu Hamada; Hideyuki Saito
Journal:  Biol Pharm Bull       Date:  2009-09       Impact factor: 2.233

8.  ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal.

Authors:  Cheol-Hee Choi
Journal:  Cancer Cell Int       Date:  2005-10-04       Impact factor: 5.722

9.  Interactions of tenofovir, Lamivudine, abacavir and Didanosine in primary human cells.

Authors:  Omar Janneh; Saye H Khoo
Journal:  Pharmaceutics       Date:  2011-06-22       Impact factor: 6.321

10.  Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells.

Authors:  Nobuaki Shiraki; Keiko Okamura; Jin Tokunaga; Takafumi Ohmura; Kazuto Yasuda; Takeo Kawaguchi; Akinobu Hamada; Masahiro Nakano
Journal:  Jpn J Cancer Res       Date:  2002-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.